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Background: Validation of new affordable CD4 T cell measurement technologies is crucial specifically in resource-
poor countries for antiretroviral treatment eligibility and immunologic CD4 monitoring of HIV-infected patients.
Methods: The absolute and percentage CD4 T cell counts of 258 HIV-1-infected blood samples (182 adults and 76
children), living in N’Djamena, Chad, were performed by single-platform, volumetric, CD45-assisted pan-leucogating
Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel Hempstead, UK) comparing to the FACSCalibur flow
cytometer as a reference method.
Results: Absolute and percentage CD4 T cell counts obtained by Auto40 and FACSCalibur of 258 HIV-1-infected
blood samples were highly correlated (r = 0.99 and r = 0.96, respectively). The mean absolute bias and percent bias
between Apogee Auto40 and FACSCalibur absolute CD4 T cell counts, were −9.4 cells/μl with limits of agreement
from −15 to 93 cells/μl, and +2.0% with limits of agreement from −0.9 to 4.9%, respectively. The mean of absolute
bias and percent bias between Apogee Auto40 and FACSCalibur of CD4 percentage results were +0.4% (95%
CI: -0.02 – 0.86) with limits of agreement from −2.4 to 0.3%, and +3.0% with limits of agreement from −6.6 to 0.6%,
respectively. The Auto40 counting allowed to identify the majority of adults with CD4 T cells below 200 cells/μl
(sensitivity: 89%; specificity: 99%) or below 350 cells/μl (sensitivity: 94%; specificity:98%); and of children below
750 cells/μl (sensitivity: 99%; specificity: 96%) or below 25% CD4+ (sensitivity: 94%; specificity: 98%).
Conclusion: The Auto40 analyzer is an alternative flow cytometer for CD4 T lymphocyte enumeration to be used in
routine for immunological monitoring according to the current WHO recommendations in HIV-infected adults as well
as children living in resource-constrained settings like Chad.
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The HIV epidemic remains a major global public health
challenge with a total of 33.4 million people living with
HIV worldwide [1]. The past decade has witnessed a
remarkable global effort to improve access to HIV anti-
retroviral therapy (ART). The current guidelines of the
World Health Organization (WHO) for scaling up of
ART in adults and children living in resource-limited
settings [2,3], emphasize the necessity of laboratory
monitoring, which is initially based on immunological
assessment by the enumeration of CD4 T lymphocytes,
mainly to start ART and monitor patients on ART. In
addition, HIV-1 RNA load is now recommended in
order to monitor treatment efficacy and early thera-
peutic failure in patients on ART as well as to monitor
therapeutic switch [4,5].
CD4 T lymphocytes monitoring typically relies on
complex flow cytometry equipment which requires infra-
structure and technical skills which are commonly
unavailable at rural and remote clinics [6]. New point-of-
care (POC) CD4 technologies enable testing to be
decentralized to these sites and for test results to be
provided during the course of the patient visit [7]. Recent
studies have demonstrated that POC CD4 T lympho-
cytes monitoring can significantly improve rates of ART
initiation and reduce patient loss-to-follow-up, which is
often high before treatment initiation [1,8,9]. Immediate
access to CD4 T cells results may also enable more rapid
initiation of prophylactic treatment for opportunistic in-
fections as well as chemotherapy for prevention of
mother-to-child transmission at sites where CD4 T lym-
phocytes levels define the prophylactic drug regimen
[10,11]. Affordable CD4 T cell counting has gradually
become possible by using simple, compact and robust
low-cost new generation of POC flow cytometers operat-
ing as single-platform volumetric instruments without
the use of expensive microbeads [7,12-14]. Introduced in
2005, the recently developed Auto40 flow cytometer
(Apogee Flow Systems Ltd, Hemel Hempstead, UK;
www.Apogeeflow.com) was originally designed for mili-
tary applications [15]. The Auto40 assay is based on no-
lyse procedure [16], which avoids the red blood cell lysis
step, thereby reducing assay variability due to changes in
assay conditions (time and temperature of incubation) as
well as differences in the susceptibility of cells to the
lysis reagents [17]. The Auto40 analyzer uses a volu-
metric syringe moved by a stepper motor that draws
and delivers a known sample volume. Therefore, its
absolute volumetric counting allows the direct deter-
mination of the number of cells per unit of sample
volume without the need for reference material such
as microbeads [13,18].
Due to the stability of its optical bench, the Auto40
may be used on peripheral stationary as well as mobileflow cytometry unit [15]. The Auto40 analyzer was
initially intended for CD4 T cell enumeration based on
primary CD4 gating, and has been validated for meas-
urement of absolute CD4 T cell count by reference to
the FACSCount system [15]. The analyzer has been
recently updated for CD4 T cells measurement within
30 minutes, using pan-leucogating protocol with primary
CD45 gating followed by secondary CD4 gating, that al-
lows results to be obtained in a single measurement of
the CD4 T cell count expressed both in absolute number
and in percentage [19,20], and therefore to address the
current WHO recommendations for CD4 T cell mea-
surements in children less than 5 years [2]. The initial
version of Auto40 analyzer based on primary CD4 gating
for CD4 T cell enumeration in absolute number has
been evaluated positively in [15]; and the current version
is based on CD45-assisted panleucogating for CD4 T cell
enumeration in absolute number as well as in percentage
in Cameroon [19,20].
The WHO strongly recommends scientific publica-
tions of effective validation of newly introduced afford-
able CD4 T cell measurement technologies carried out
in the field by several laboratories of different resource-
poor countries, and independently of manufacturers
[6,21]. Therefore, the objective of the present study was
to perform a novel and independent evaluation of the
biological performances of the Auto40 analyzer in the
HIV dedicated reference laboratory of the hôpital
Militaire d’Instruction, located in N’Djamena, the capital
city of Republic of Chad.
Methods
Clinical specimens and processing
Tripotassium ethylenediamine tetraacetate (K3-EDTA)-
blood samples obtained by venipuncture in Vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) were
consecutively received in April 2012 (during the dry sea-
son) for routine biological monitoring at the reference
laboratory of the hôpital de la Liberté, N’Djamena, an in-
stitutional reference laboratory devoted to HIV screening
and monitoring. Two aliquots of one sample were kept
at ambient temperature. No extra specimens were re-
quired. All blood samples were unlinked to identifiers.
Each aliquot was first subjected to immediate measure-
ment by flow cytometry reference analyzer, at ambient
temperature at the hôpital de la Liberté, N’Djamena, and
the second aliquot was sent within 4 hours to the hôpital
Militaire D’Instruction, N’Djamena, for CD4 T cell count
by Auto40 flow cytometer.
The study was approved by the Chad Ministry of
Public Health. Written informed consents from all sub-
jects were obtained before study initiation. For children
samples, legal children’s guardians or parents signed an
informed consent.
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flow cytometer comparing with the FACSCalibur
reference flow cytometry method
CD4 T cell quantification was performed in parallel on 2
different flow cytometers: (1) the FACSCalibur [Becton
Dickinson Immuno-cytometry System (BDIS), San Jose,
CA, USA], a dedicated clinical reference flow cytometer
for CD4 T cell counting installed at the hôpital de la
Liberté, N’Djamena, using Multitest reagent (BDIS) and
MultiSet V2.2 software (BDIS) for calculating the abso-
lute and percentage values of CD4 T cells according to
the manufacturer instructions, as previously described
[22,23]; and (2) the Auto40 flow cytometer (Apogee
Flow Systems Ltd) equipped with a green laser at
532 nm, a side scatter detector, two fluorescence chan-
nels and means for direct volumetric counting, without
requiring a red blood cell lysis step.
Direct volumetric CD4 T cell measurements were
performed on the Auto40 using phycoerythrin (PE)-
conjugated anti-CD4 and PE-Dyomics649-conjugatedFigure 1 Gating strategy for volumetric, CD45-assisted panleucogatin
Hempstead, UK), as depicted from typical figure provided by “Auto-L
counting of CD4 T lymphocytes: A. CD45-PE-Dyomics649 x axis-light sca
the CD45-positive lymphocytes and monocyte populations, and the popu
plot scattergram; double secondary CD4 gatings allow counting independe
lymphocytes; C. Representative figure depicted by the software “Auto-Lymp
scatter (LS2) dot plot scattergram; (b) CD4 (FL1)xside scatter (LS2) dot plot
sample counting; (d) Distribution of bright CD4 events within the primary Canti-CD45 monoclonal antibodies (Apogee Flow Systems
Ltd). The Auto40 analytical procedure avoids the need
for a wash step. Briefly, 50 μl of whole EDTA-blood was
added into polypropylene test tubes containing pre-
dispensed, stabilized monoclonal antibodies. After 25 mi-
nutes of incubation at room temperature in the dark,
the blood samples were diluted 1:10 in phosphate buff-
ered saline. The no-lyse-no-wash stained samples were
run on the Auto40 flow cytometer, and CD4 T cell count
was obtained in absolute number and in percentage.
Analysis on the Auto40 flow cytometer was automatic-
ally performed by the built-in software “Auto-lympho-
cyte” (Apogee Flow Systems Ltd), with the possibility of
controlling and assessing the quality of the data analysis.
CD45-positive lymphocytes and monocytes were identi-
fied by primary gating on bright CD45 fluorescent cells
in a CD45xside scatter dot plot scatter gram (Figure 1A).
The CD45 fluorescent polymorphonuclear cells were ex-
cluded from the gating according to their high nuclear
density. Within the CD45-positive cells, CD4-positiveg Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel
ymphocyte” software (Apogee Flow Systems Ltd) for the
tter dot plot scattergram; the primary CD45 gating differentiates clearly
lation of polymorphonuclear cells; B. CD4-PE x axis-light scatter dot
ntly the population of CD4-negative lymphocyte and CD4-positive
hocyte” in one blood sample taken as example: (a) CD45 (FL2)xside
scattergram; (c) Distribution of bright CD45 events during blood
D45 gating scattergram, during blood sample counting.
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ondary gating in a CD4xside scatter dot plot scatter
gram (Figure 1B). CD4-positive T lymphocytes are easily
separated for monocytes and CD4-negative lymphocytes,
and counted independently. The CD4 T lymphocytes
count in absolute number corresponds to the CD4-
positive secondary CD4 gating cell populations. The
CD4 T lymphocytes count in percentage corresponds to
the ratio of CD4-positive lymphocytes count in absolute
number to the total CD4-positive and CD4-negative
lymphocytes counts, corresponding to the sum of both
secondary CD4 gating. The sample reading takes around
2 minutes. Aside from simplifying sample preparation,
the software “Auto-lymphocyte” allows automatic read-
ing, and greatly facilitates manipulations by laboratory
technicians. The whole procedure is fast and only needs
30 minutes to be completed. According to the manufac-
turer, the Auto40 flow cytometer has the theoritical cap-
acity of 150 CD4 T cells enumerations per day.
To ensure quality control of the flow cytometric
immune-phenotyping method with regard to the per-
formance of the personnel and the instrument, the
same lots of reagents were used throughout the study,
and all sample preparations and flow cytometric
analyses were performed by the same operator for each
instrument, as previously reported [24]. Adequate
training on the use of reverse pipetting technique and
electronic pipette was also provided for each operator.
Furthermore, the FACSCalibur photomultiplier tube
voltage, sensitivity, and fluorescent compensation
settings were optimized prior to sample acquisition. In
addition, weekly calibration and internal quality
control of the FACSCalibur were performed by using
Calibrite beads (BDIS) and FACSComp software
(BDIS). Quality control on the Auto40 flow cytometer
was primarily assessed by the use of a calibrated bead
sample (Apogee cat # 1444 for Auto40-green, Apogee
Flow Systems Ltd) at the beginning and end of each
session, and on the use of stabilized blood reference
samples (Cytofix CD4, CaltagMedsystems Ltd, UK) as
an additional external control.
Statistical analyses
The Method Validator software version 1.1.9.0. (Philippe
Marquis, France) and the SAS-PC software (version 8.2,
SAS Institute, Cary, North Carolina, USA) were used for
statistical analyses. First, correlations between the abso-
lute CD4 T cell counts obtained by the reference
FACSCalibur and the Auto40 were established by the
Passing-Bablok nonparametric method [25]. Secondly,
the agreement between FACSCalibur and Auto40 was
depicted by difference plots as proposed by Bland and
Altman [25-27] and Pollock et al. [28]. The Bland-
Altman and Pollock analyses were carried out tocalculate the mean of absolute and relative bias and
limits of agreement, respectively, corresponding to the
95% confidence intervals [± 1.96 × standard deviation
(SD)] of the mean absolute and relative bias of all paired
measurements [27].
To assess the clinical impact of using the Auto40 in-
stead of the FACSCalibur in Chad setting, the sensitivity
and the specificity of the Auto40 was calculated to iden-
tify patients who had with the FACSCalibur a CD4 T cell
count below 200 cells/μl, the threshold of immune-
restoration under ART and the threshold for therapeutic
initiation according to the 2006-revised WHO recom-
mendations (WHO, 2007), 350 cells/μl, the new thresh-
old for ART initiation for adults and children aged more
than 5 years according to the 2010-revised WHO guide-
lines [2], or 750 cells/μl and%CD4+ ≤25%, the new
absolute and percent CD4 T cell count WHO thresholds
for ART initiation in children aged between 24 and
59 months [2]. For clinical significance of the measure-
ment differences on treatment decision, the Cohen’s k
coefficient was calculated on study population [29].
Results
Accuracy of direct volumetric CD4 T cell measurements
by the Auto40 flow cytometer in Chad
A total of 258 EDTA-blood samples with correct pre-
analytical preparation were obtained from 182 HIV-1-
infected adults (median age, 33.3 years; range, 18–59,
60 males), and 76 HIV-1-infected children older than
5 years (median age, 6.2 years; range, 5–17, 35 males).
The majority of study patients (74%) were taking ART
according to the WHO recommendations for resource-
limited settings, whereas 26% of them were naïve for
ART. No pregnant woman was included in the study.
The absolute and relative bias (and the limits of agree-
ment) for CD4 T cell counting in absolute count and
percentage are shown in Table 1 for the study in adults
and children, by the Apogee Auto40 flow cytometer and
the FACSCalibur, and in Table 2 at various CD4 T cell
count ranges. In addition, the Figure 2 depicts the
Passing-Bablok agreement test and the Bland-Altman
analyses between the CD4 T cell count results obtained
by Auto40 and FACSCalibur flow cytometers, in abso-
lute number and in percentage, in the 182 study HIV-1-
infected adults and 76 HIV-1-infected children older
than 5 years.
Mean ± SD of CD4 T cells/μl expressed in absolute
number was 864 ± 761 cells/μl (range, 5–5639) by
Auto40 flow cytometer, and 975 ± 765 cells/μl (range,
5–5674) by FACSCalibur (P > 0.5). The non-parametric
Passing-Bablok regression analysis on all 258 available T
cell results expressed in absolute count revealed a high
correlation between CD4 T cell counts obtained by
Auto40 flow cytometer and FACSCalibur (r = 0.99) with
Table 1 CD4 T cell counting in absolute cells/μl and percentage in 182 HIV-1-infected adults and 76 HIV-1-infected
children older than 5 years, by the Apogee Auto40 flow cytometer at the hôpital Militaire D’Instruction, N’Djamena,
Chad, and by the FACSCalibur at the hôpital de la Liberté, N’Djamena
Categories Adults Children
Number N = 182 N = 76
Absolute CD4 T cells (cells/μl)
Apogee Auto40 Mean ± SD 627 ± 591 1432 ± 821
FACSCalibur Mean ± SD 635 ± 588 1449 ± 835
Absolute bias (limits of agreement)a Mean (±1.96 SD) −16.0 (−38.2;6.1) 30.0 (−14.7;88.7)
Relative (%) bias (limits of agreement)b Mean (±1.96 SD) 1.0 (−1.8;3.8) 0.3 (−2.2;2.7)
Percentage of CD4 T cells (%CD4)
Apogee Auto40 Mean ± SD 29.1 ± 12.8 32.1 ± 10.1
FACSCalibur Mean ± SD 28.5 ± 12.5 32.3 ± 10.6
Absolute bias (limits of agreement)a Mean (±1.96 SD) −3.0 (−7.1;1.1) 1.0 (−0.4;2.4)
Relative (%) bias (limits of agreement)b Mean (±1.96 SD) −11.0 (−25.8;3.8) 3.0 (−1.3;5.3)
a The Bland Altman analysis was carried out to calculate the absolute bias and limits of agreement which are the 95% confidence intervals (±1.96 × SD) of the
mean bias of all paired measurements in a given category [27];
b The Pollock analysis was carried out to calculate the relative bias and limits of agreement which are the 95% confidence intervals (±1.96 × SD) of the mean bias
of all paired measurements in a given category [28].
SD: Standard deviation.
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+4.4 (95% CI: -18.0 – 26.8). The mean absolute bias
measured by Bland-Altman analysis, and the mean rela-
tive bias measured by Pollock analysis, between CD4 T
cells/μl obtained by Apogee Auto40 flow cytometer and
FACSCalibur over the entire range of CD4 T cell results,
were −9.4 cells/μl (95% CI: -23.5 – 4.7) with limits ofTable 2 CD4 T cell counting in absolute count and percentag
Auto40 flow cytometer at the hôpital Militaire D’Instruction,
de la Liberté, N’Djamena, at various CD4 T cell count ranges
Categories < 2
Number N =
Absolute CD4 T cells (cells/μl)*
Apogee Auto40 Mean ± SD 118
FACSCalibur Mean ± SD 100
Absolute bias (limits of agreement)a Mean (±1.96 SD) −4.
Relative (%) bias (limits of agreement)b Mean (±1.96 SD) 62.0
Percent CD4 T cells (%CD4)**
Apogee Auto40 Mean ± SD 10.0
FACSCalibur Mean ± SD 9.0
Absolute bias (limits of agreement)a Mean (±1.96 SD) 1.0
Relative (%) bias (limits of agreement)b Mean (±1.96 SD) 6.0
* Results in absolute CD4 T cell counts by Auto40 and FACSCalibur were correlated
r = 0.86, slope = 1.11, intercept = −12.0; 200 – 350 cells/μl: r = 0.68, slope = 1.31, in
** Results in percentage CD4 T cell counts by Auto40 and FACSCalibur were correla
μl: r = 0.89, slope = 1.00, intercept = 0.0; 200 – 350 cells/μl: r = 0.89, slope = 1.00, in
a The Bland Altman analysis was carried out to calculate the absolute bias and limit
mean bias of all paired measurements in a given category [27];
b The Pollock analysis was carried out to calculate the relative bias and limits of agr
of all paired measurements in a given category [28].
SD: Standard deviation.agreement from −15 to 93 cells/μl, and +2.0% with limits
of agreement from −0.9 to 4.9%, respectively.
Mean ± SD CD4 T cell count in percentage was 30.1 ±
12.1%CD4+ (range, 1–87) by Auto40 flow cytometer,
and 29.6 ± 12.1%CD4+ (range, 1–83) by FACSCalibur
(P > 0.5). Results of CD4 T cell count in percentage by
Auto40 flow cytometer and FACSCalibur were highlye in 258 HIV-1-infected individuals, by the Apogee
N’Djamena, Chad, and by the FACSCalibur at the hôpital
according to the FACSCalibur results
00 cells/μl 200 – 350 cells/μl > 350 cells/μl
27 N = 43 N = 188
± 161 278 ± 129 2990 ± 3745
± 135 215 ± 103 3017 ± 3756
0 (−33.8;+25.8) 10.0 (−70.0;+90.0) 12.0 (−160.7;+184.7)
(−134.0;+258.0) 7.0 (−27.2;+41.2) −3.0 (−12.4;+6.4)
± 12.7 19.5 ± 6.3 55.1 ± 44.5
± 11.3 18.0 ± 4.2 53.3 ± 41.7
(−1.8;+3.8) 2.0 (−2.3;+6.3) 2.0 (−3.4;+7.4)
(−10.3;+22.3) 7.0 (−13.2;+27.2) 2.0 (−4.6;+8.6)
using the non-parametric Passing–Bablok regression analysis (< 200 cells/μl:
tercept = −96.5; > 350 cells/μl: r = 0.98, slope = 1.02, intercept = −24.8);
ted using the non-parametric Passing–Bablok regression analysis (< 200 cells/
tercept = 0.0; > 350 cells/μl: r = 0.95, slope = 1.00, intercept = 0.0);
s of agreement which are the 95% confidence intervals (±1.96 × SD) of the
eement which are the 95% confidence intervals (±1.96 × SD) of the mean bias
Figure 2 Results from CD4 T cell count measurements in 182 HIV-1-infected adults and 76 HIV-1-infected children older than 5 years,
expressed in absolute number (cells/μl) and in percentage carried out in parallel by the Auto40 flow cytometer and by the FACSCalibur. A, A’,
C and C’. Passing-Bablok agreement tests between the CD4 T cell count results obtained by Auto40 and FACSCalibur flow cytometers, in absolute
number (A and A’) and in percentage (C and C’). The diagonal dotted line represents the ideal line (no bias). The full line represents the regression line
of the distribution; B, B’, D and D’. Bland-Altman analyses on the relative differences between the CD4 T cell counts obtained by Auto40 and FACSCalibur
flow cytometers compared with the average CD4 T cell count, in absolute number (B and B’) and in percentage (D and D’). The full line represents the
mean relative difference, and the dotted lines represent the superior and inferior limits of agreement. The arrow corresponds to the x abscise axis.
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of 0.96 (95% IC: 0.92 – 0.99) and an intercept of +1.7
(95% CI: 0.6 – 2.9). The mean of absolute bias and rela-
tive bias between percentage of CD4 T cells obtained by
Auto40 flow cytometer and FACSCalibur were +0.4%
CD4 (95% CI: -0.02 – 0.86) with limits of agreement
from −2.4 to 0.3%CD4, and +3.0% with limits of agree-
ment from −6.6 to 0.6%, respectively.
The number of outliers showed a trend to be higher
when the CD4 T cell count was expressed in absolute
count (16/258 = 6.2%) than when it was given in per-
centage (10/258 = 3.9%), although the difference was not
statistically significant (P = 0.22 by Student t test).
Sensitivity and specificity to identify clinically-relevant
thresholds by the Auto40 flow cytometer
The sensitivity and specificity of CD4 T cell counting by
the Auto40 flow cytometer to identify the patients withless or more than 200 CD4 T cells/μl, 350 CD4 T cells/
μl, 750 CD4 T cells/μl and 25%CD4+, were calculated on
the 258 available CD4 T cell count measurements, and
are depicted in the Table 3. Whatever the thresholds
considered, the concordance between the Auto40 flow
cytometer and FACSCalibur methods was high, and the
decision did not differ between study blood samples
according to both methods (κ = 0.96 to 0.98; P < 0.01).
Discussion
In the present study, we carried out a new evaluation
of the biological performances of the Auto40 flow
cytometer in Chad focusing on the HIV-infected adult
and children populations, independently of the manufac-
turer, and in complement to those previously reported in
Senegal [15] and Cameroon [19]∙ Indeed, several evalua-
tions by at least 3 independent laboratories in the field
are strongly recommended for effective validation of the
Table 3 The sensitivity and specificity of CD4 T cell counting by the Auto40 to identify patients having less than
(or more than) 200 CD4 T cells/μl, 350 CD4 T cells/μl, 750 CD4 T cells/μl and 25%CD4+, calculated on the 258 available
CD4 T cell count measurements
Sensitivity Specificity Cohen’s κ coefficient$
200 CD4 T cells/μl* 89% 99% 0.97
Thresholds 350 CD4 T cells/μl** 94% 98% 0.98
750 CD4 T cells/μl*** 99% 96% 0.97
25%CD4 94% 98% 0.96
* 200 CD4 T cells/μl: Threshold of immune-restoration under antiretroviral treatment and the threshold for therapeutic initiation according to the 2006-revised
WHO recommendations [30];
** 350 CD4 T cells/μl: New WHO threshold for antiretroviral treatment initiation in adults and children aged more than 5 years [3];
*** 750 CD4 T cells/μl and 25%CD4+: WHO thresholds for antiretroviral treatment initiation in children aged between 24 and 59 months [2];
$A 10% bilateral range (i.e., counts between 190 and 210 CD4 T cells/μl for the threshold at 200 CD4 T cells/μl; counts between 332 and 367 CD4 T cells/μl for the
threshold at 350 CD4 T cells/μl; counts between 712 and 787 CD4 T cells/μl for the threshold at 750 CD4 T cells/μl; and counts 23.7 and 26.2%CD4+ for the
threshold at 25%CD4+) were considered similar.
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technologies to be used in resources-constrained settings
[6,21]. Our results confirm that the Auto40 flow
cytometer, whether operated in the field in Chad by a la-
boratory technician, has an acceptable performance
compared with the FACSCalibur for CD4 T cell quantifi-
cation expressed in absolute number as well as in per-
centage in HIV-infected adult and children patients. The
Auto40 flow cytometer results in absolute number and
percentage which gave high correlations with those
obtained by the reference flow cytometer method. The
correlation was maintained at different CD4 T cell count
ranges over all the dynamic range of values in absolute
number (until 5639 CD4 T cells/μl) as well as in per-
centage (until 83%CD4+). CD4 T cell counting by
CD45-assisted Auto40 allowed to identify the majority
of adults with CD4 T cells below 200 cells/μl or 350
cells/μl, and of children below 750 cells/μl or 25%CD4+,
demonstrating the capacity of Auto40 to accurately as-
sess the major thresholds in absolute number (200 cells/
μl, 350 cells/μl and 750 cells/μl) or in percentage (25%
CD4+), used in clinical practice to initiate or follow
ART in adults and children. Taken together, these find-
ings demonstrate that the simplified, single-platform,
volumetric, CD45-assisted pan-leucogating Auto40 flow
cytometer is a reliable alternative flow cytometer for
CD4 T lymphocyte enumeration to be used in routine
for immunological monitoring according to the 2010-
revised WHO recommendations in HIV-infected adults
as well as children living in resource-constrained
settings.
Our study confirms and extends the interest of the
Auto40 analyzer for CD4 T cell enumeration in develop-
ing countries, as recently reported in Senegal by Dieye
et al. [15], and in Cameroon by Mbopi-Kéou et al. [20].
The Senegalese validation used the initial Auto40 ver-
sion based on primary CD4 gating and focused exclu-
sively on CD4 T cell counting in absolute number [15].
However, as the percentage of CD4 T cells is essentialfor monitoring HIV disease progression in children less
than 5 years [2,14], the primary CD4 gating format of
the Auto40 analyzer that only measure absolute CD4 T
cell numbers, was being modified by the manufacturer
in 2006 to measure the percentage CD4 T cells. Thus,
our observations extent the previous study in Senegal,
by demonstrating that the updated version of the
Auto40 flow cytometer, now based on a pan-leucogating
protocol using anti-CD45 and anti-CD4 monoclonal
antibodies, is not only valid for CD4 T cell enumeration
in absolute number, but also in percentage. Finally, the
present validation of the Auto40 analyzer in Chad rein-
forces and improves the previous Senegalese and
Cameroonese conclusions on the clinical interest of the
Auto40 flow cytometer for immunological monitoring of
HIV-infected adult and children. The present study how-
ever was conducted under controlled conditions in a ref-
erence laboratory and by qualified technicians. Further
studies are needed to confirm the reliability of the
Auto40 analyzer for routine usage in the field.
Immunophenotyping by flow cytometry is the refer-
ence method for the enumeration of the CD4 marker on
T lymphocytes [31]. Initially, the use of large panel of re-
agents and stringent gating techniques for full lympho-
cyte subset analysis has been shown to be superfluous
and expensive [32]. The simplified flow cytometric pan-
leucogating protocol is based on a sequential strategy by
initially gating on the total white blood cell population
(CD45-positive population), which then serves as the
common denominator to enumerate CD4-positive T
lymphocytes instead of primarily gating on the error
prone lymphocyte population [33]. The specific use of
the side scatter parameter allows for the discrimination
of monocytes due to the high side scatter and low CD4
expression of monocytes thereby enabling accurate
CD4-positive T cell enumeration. The CD4-positive lym-
phocytes are low side scatter and high CD4 expressing
cells [34]. The pan-leucogating method has been demon-
strated to allow accurate CD4 T cell counting, when
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either volumetric [37] or bead-based [38,39].
The performance of single-platform, volumetric flow
cytometric systems operating with CD45-based gating
and generic monoclonal antibodies has been previously
reported for a limited number of commercially available
analyzers, including mainly the microcapillary-based Guava
AutoCD4/CD4%™ (Merck Millipore LS International
Hayward, CA, USA) [24] and the CyFlow SL_3™ (Partec
GmbH, Munster, Germany) [40]. Both latter analyzers have
proven their usefulness for validated absolute and percent-
age of CD4 T cell counting in the field [24,40]. These
single-platforms using only a flow cytometer and volumet-
ric systems allow counting CD4 T cells in a fixed volume,
thus leading to a considerable reduction in the costs of
CD4-positive T cell enumeration by comparison to
microbead-based systems [31]. In addition, the compact
low-range single-platforms Auto40 and CyFlow SL_3™ are
portable desk-top flow cytometers that does not require op-
tical alignment, can run on a 12-volt car battery, and can
be connected to a laptop computer, suggesting their pos-
sible use in health care mobile unit that could make CD4 T
cell enumeration available in remote or hard-to-reach loca-
tions, as previously shown for the Auto40 flow cytometer
installed in health mobile unit in Cameroon [20]. These
observations raise the issue of decentralization of immuno-
logical monitoring in large areas where laboratories are
remote, using health mobile units capable of performing
screening and immunological monitoring of HIV-infected
patients [20,41].
One of the additional main features of the Auto40
analyzer is the use of stabilized monoclonal antibodies.
The assay reagents can be stored for prolonged period of
time (up to 12 months) at high temperature without any
loss of biological activity [42]. The use of thermo-
resistant reagents allowed reliable measurements of CD4
T cell count, both in absolute and percentage terms,
under unfavourable conditions like high temperatures in
the tropics, as in remote areas where the conditions met
for the storage of reagents (cold chain), particularly
during shipment and delivery, is not guaranteed [43].
The thermo-stable monoclonal antibodies used in the
present study can be kept for as long as one year at
room temperature, i.e. 30°C, and has been chosen for all
laboratories equipped by an Auto40 flow cytometer in
Chad. The possibility of long-term storage of reagents at
room temperature for one year should facilitate the
planning of laboratory activities and reduce the costs re-
lated to loss of reagents stability. Overall, the use of
thermo-stable reagents increases the accessibility to flow
cytometry testing. However, while the manufacturing
costs related to the antibody stabilization procedure does
not exceed 15% of the original cost [42], the final sale
prices of thermo-resistant reagents marketed by Inodia(France) is higher than 40% compared to those of liquid
reagents.
In the present study, all specimens used for the
evaluation were fresh and not travelled. This practice
represents the current situation in Chad. Indeed, there is
no organization of blood samples transportation thor-
ough the country, mainly because of heavy logistical
constrained in a very large country, which is furthermore
affected by a hard tropical climate. In contrast, the so-
called “Conseil National de Lutte contre le SIDA”,
N’Djamena, Chad decided to decentralize the CD4 ana-
lyzers, and acquired from 2003 to 2012 around twenty
CD4 analyzers to be installed in laboratory facilities
thorough the country.
The accurate determination of CD4 T cells is of crucial
clinical importance for caring adults or children infected
with HIV or suffering from AIDS. Although classical
flow cytometry represents the reference method for CD4
T cell enumeration, the feasibility of flow cytometric
methods in the field remains controversial in resource-
poor settings [8]. In the Cameroonese experience, well-
trained technicians were able to use the Auto40 flow
cytometer with low intra- and inter- run precisions
ranging from 4.8% to 5.5% and from 5.3% to 7.9%,
respectively, thus less than 10% [19,20], considered as
acceptable for routine clinical practice [15], and compar-
able to other published reports using single-platform
flow cytometers [10,24,40,44]. The low observed variabil-
ity of the Auto40 flow cytometer confirmed that single-
platform flow cytometric methods are more reproducible
than dual-platform [45]. Higher precisions for high than
for low CD4 T cell count have been previously reported
with single-platform volumetric flow cytometric method
[40]. Finally, the Auto40 system showed a high capacity
of accurately discriminate CD4 T cell values around the
relevant CD4 T cells thresholds recommended by the
2010-revised WHO guidelines to initiate and follow
ART in HIV-infected adults or children, as previously
reported [15,19,46].
Conclusions
In conclusions, the Auto40 flow cytometer constitutes
a promising system for performing single-platform
absolute and percent CD4 T lymphocyte counts with
excellent reproducibility, and should facilitate wider
access to CD4 T cell enumeration for adults and
children infected with HIV infection living in resource-
constrained countries.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DK, ANM and LB conceived and designed the research, and analyzed the
results, performed the statistical analyses and drafted the manuscript with
Koyalta et al. BMC Research Notes 2013, 6:169 Page 9 of 10
http://www.biomedcentral.com/1756-0500/6/169MAJ; DK and NN have performed the experiments; BD was directly involved
in the implementation of Auto40 analyzers in Chad; NDO discussed the
medical validity of CD4 T counting by the Auto40 analyzer. All authors read
and approved the final manuscript.
Acknowledgments
The authors are grateful to the hôpital d’Instruction des Armées, N’Djamena,
Chad, for making this evaluation possible and to the hôpital de la Liberté,
N’Djamena, for performing the analyses on the FACSCalibur. We thank Hota
Mathieu for hepful technical assistance. The study was carried out
completely independently of the Auto40 manufacturer. Dr. M.A. Jenabian is
supported by a CANFAR/CTN Postdoctoral Fellowship Award.
Author details
1Ministère de la Santé Publique, N’Djamena BP 407, Chad. 2Chronic Viral
Illness Service and Research Institute of the McGill University Health Centre,
Montreal, Canada. 3Hôpital de la Liberté, N’Djamena, Chad. 4Conseil National
de Lutte contre le SIDA, Primature, N’Djamena, Chad. 5Organisation Mondiale
de la Santé, Représentation du Tchad, N’Djamena, Chad. 6Laboratoire
National de Référence des Maladies Sexuellement Transmissibles et du SIDA,
Département de Microbiologie, Faculté de Médecine de Libreville, Université
des Sciences de la Santé, Libreville, Gabon. 7Laboratoire de virologie, hôpital
Européen Georges Pompidou, and Faculté de Médecine Paris Descartes,
Université Paris Descartes (Paris V), Sorbonne Paris Cité Paris, France.
Received: 10 October 2012 Accepted: 25 April 2013
Published: 30 April 2013
References
1. UNAIDS: Global report on the global AIDS epidemic. 2010. Available at http://
www.unaids.org/globalreport/global_report.htm.
2. World Health Organization: World Health Organization (WHO)
recommendations. Antiretroviral therapy for HIV infection in infants and
children: toward universal access. 2010. http://whqlibdoc.who.int/
publications/2010/9789241599801_eng.pdf.
3. World Health Organization: World Health Organization (WHO)
recommendations antiretroviral therapy for HIV infection in adults and
adolescents. Antiretroviral therapy for a public health approach 2010 revision.
2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
4. Belec L, Bonn JP: Challenges in implementing HIV laboratory monitoring
in resource-constrained settings: how to do more with less. Future
Microbiol 2011, 6(11):1251–1260.
5. Belec L, Mbopi-Keou FX, Gershy-Damet GM, Mboup S: HIV laboratory
monitoring for effective ART in Africa. Lancet Infect Dis 2012, 12(6):430.
6. Mandy F, Janossy G, Bergeron M, Pilon R, Faucher S: Affordable CD4 T-cell
enumeration for resource-limited regions: a status report for 2008.
Cytometry B Clin Cytom 2008, 74(Suppl 1):S27–S39.
7. Murtagh MM: UNITAIDS Technical Report. HIV/AIDS diagnostic landscape.
2011. http://www.unitaid.eu/images/marketdynamics/publications/
unitaid_md_technical_report_diagnostics_landscape_web.pdf.
8. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, Lehe JD,
Peter TF: Accurate CD4 T-cell enumeration and antiretroviral drug
toxicity monitoring in primary healthcare clinics using point-of-care
testing. AIDS 2011, 25(6):807–812.
9. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S: Why are antiretroviral
treatment patients lost to follow-up? A qualitative study from South
Africa. Trop Med Int Health 2010, 15(Suppl 1):48–54.
10. Lynen L, Teav S, Vereecken C, De Munter P, An S, Jacques G, Kestens L:
Validation of primary CD4 gating as an affordable strategy for absolute CD4
counting in Cambodia. J Acquir Immune Defic Syndr 2006, 43(2):179–185.
11. Miiro G, Nakubulwa S, Watera C, Munderi P, Floyd S, Grosskurth H:
Evaluation of affordable screening markers to detect CD4+ T-cell counts
below 200 cells/mul among HIV-1-infected Ugandan adults. Trop Med Int
Health 2010, 15(4):396–404.
12. Peter TF, Shimada Y, Freeman RR, Ncube BN, Khine AA, Murtagh MM: The
need for standardization in laboratory networks. Am J Clin Pathol 2009,
131(6):867–874.
13. Dieye TN, Vereecken C, Diallo AA, Ondoa P, Diaw PA, Camara M, Karam F,
Mboup S, Kestens L: Absolute CD4 T-cell counting in resource-poor
settings: direct volumetric measurements versus bead-based clinical
flow cytometry instruments. J Acquir Immune Defic Syndr 2005, 39(1):32–37.14. O’Gorman MR, Zijenah LS: CD4 T cell measurements in the management
of antiretroviral therapy–A review with an emphasis on pediatric HIV-
infected patients. Cytometry B Clin Cytom 2008, 74(Suppl 1):S19–S26.
15. Dieye TN, Diaw PA, Daneau G, Wade D, Sylla Niang M, Camara M, Diallo AA,
Toure Kane C, Diop Ndiaye H, Mbengue B, et al: Evaluation of a flow
cytometry method for CD4 T cell enumeration based on volumetric
primary CD4 gating using thermoresistant reagents. J Immunol Methods
2011, 372(1–2):7–13.
16. Hoffman RA, Kung PC, Hansen WP, Goldstein G: Simple and rapid
measurement of human T lymphocytes and their subclasses in
peripheral blood. Proc Natl Acad Sci USA 1980, 77(8):4914–4917.
17. Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, Scarpati B,
D’Avanzo G, D’Hautcourt JL, Lenkei R, et al: Cytofluorometric methods for
assessing absolute numbers of cell subsets in blood. European Working
Group on Clinical Cell Analysis. Cytometry 2000, 42(6):327–346.
18. Mercolino TJ, Connelly MC, Meyer EJ, Knight MD, Parker JW, Stelzer GT,
DeChirico G: Immunologic differentiation of absolute lymphocyte count
with an integrated flow cytometric system: a new concept for absolute T
cell subset determinations. Cytometry 1995, 22(1):48–59.
19. Mbopi-Keou FX, Mion S, Sagnia B, Belec L: Validation of a single-platform,
volumetric, CD45-assisted PanLeucogating Auto40 flow cytometer to
determine the absolute number and percentages of CD4 T cells in
resource-constrained settings using Cameroonian patients’ samples. Clin
Vaccine Immunol 2012, 19(4):609–615.
20. Mbopi-Keou FX, Sagnia B, Ngogang J, Angwafo FF 3rd, Colizzi V,
Montagnier L, Belec L: Validation of a single-platform, volumetric, flow
cytometry for CD4 T cell count monitoring in therapeutic mobile unit.
J Transl Med 2012, 10:22.
21. World Health Organization: World Health Organization (WHO) Consultation
on Technical and Operational Recommendations for Scale-Up of Laboratory
Services and Monitoring HIV Antiretroviral Therapy in Resource-Limited Settings
(13–15 December 2004: Geneva, Switzerland). 2005. http://www.who.int/hiv/
pub/meetingreports/labmeetingreport.pdf.
22. Sagnia B, Ateba Ndongo F, Ndiang Moyo Tetang S, Ndongo Torimiro J,
Cairo C, Domkam I, Agbor G, Mve E, Tocke O, Fouda E, et al: Reference
values of lymphocyte subsets in healthy, HIV-negative children in
Cameroon. Clin Vaccine Immunol 2011, 18(5):790–795.
23. Schnizlein-Bick CT, Spritzler J, Wilkening CL, Nicholson JK, O’Gorman MR:
Evaluation of TruCount absolute-count tubes for determining CD4 and
CD8 cell numbers in human immunodeficiency virus-positive adults. Site
Investigators and The NIAID DAIDS New Technologies Evaluation Group.
Clin Diagn Lab Immunol 2000, 7(3):336–343.
24. Pattanapanyasat K, Phuang-Ngern Y, Sukapirom K, Lerdwana S, Thepthai C,
Tassaneetrithep B: Comparison of 5 flow cytometric immunophenotyping
systems for absolute CD4+ T-lymphocyte counts in HIV-1-infected
patients living in resource-limited settings. J Acquir Immune Defic Syndr
2008, 49(4):339–347.
25. Passing H, Bablok: A new biometrical procedure for testing the equality
of measurements from two different analytical methods. Application of
linear regression procedures for method comparison studies in clinical
chemistry, Part I. J Clin Chem Clin Biochem 1983, 21(11):709–720.
26. Bland JM, Altman DG: Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986,
1(8476):307–310.
27. Bland JM, Altman DG: Measuring agreement in method comparison
studies. Stat Methods Med Res 1999, 8(2):135–160.
28. Pollock MA, Jefferson SG, Kane JW, Lomax K, MacKinnon G, Winnard CB:
Method comparison–a different approach. Ann Clin Biochem 1992,
29(Pt 5):556–560.
29. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas
1960, 20:37–46.
30. World Health Organization: Antiretroviral therapy for HIV treatment of adults
and adolescents: recommendations for a public health approach 2006 revision.
2007. http://www.who.int/hiv/pub/guidelines/adult/en/index.html.
31. Baum LL, Crowe S, Landay AL: Advances in CD4 cell enumeration in
resource-poor countries. Curr Opin HIV AIDS 2007, 2(3):234–240.
32. Mandy FF, Nicholson JK, McDougal JS: Guidelines for performing
single-platform absolute CD4+ T-cell determinations with CD45
gating for persons infected with human immunodeficiency virus.
Centers for Disease Control and Prevention. MMWR Recomm Rep 2003,
52(RR-2):1–13.
Koyalta et al. BMC Research Notes 2013, 6:169 Page 10 of 10
http://www.biomedcentral.com/1756-0500/6/16933. Simson E, Groner W: Variability in absolute lymphocyte counts obtained
by automated cell counters. Cytometry 1995, 22(1):26–34.
34. Glencross D, Scott LE, Jani IV, Barnett D, Janossy G: CD45-assisted
PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell
enumeration. Cytometry 2002, 50(2):69–77.
35. Pattanapanyasat K, Shain H, Noulsri E, Lerdwana S, Thepthai C, Prasertsilpa V,
Likanonsakul S, Yothipitak P, Nookhai S, Eksaengsri A: A multicenter
evaluation of the PanLeucogating method and the use of generic
monoclonal antibody reagents for CD4 enumeration in HIV-infected
patients in Thailand. Cytometry B Clin Cytom 2005, 65(1):29–36.
36. Pattanapanyasat K, Shain H, Prasertsilpa V, Noulsri E, Lerdwana S, Eksaengsri
A: Low cost CD4 enumeration using generic monoclonal antibody
reagents and a two-color user-defined MultiSET protocol. Cytometry B
Clin Cytom 2006, 70(5):355–360.
37. Janossy G, Jani IV, Bradley NJ, Bikoue A, Pitfield T, Glencross DK: Affordable
CD4(+)-T-cell counting by flow cytometry: CD45 gating for volumetric
analysis. Clin Diagn Lab Immunol 2002, 9(5):1085–1094.
38. Sippy-Chatrani N, Marshall S, Branch S, Carmichael-Simmons K, Landis RC,
Abayomi A: Performance of the Panleucogating protocol for CD4+ T cell
enumeration in an HIV dedicated laboratory facility in Barbados.
Cytometry B Clin Cytom 2008, 74(Suppl 1):S65–S68.
39. Storie I, Sawle A, Whitby L, Goodfellow K, Granger V, Reilly JT, Barnett D:
Flow rate calibration II: a clinical evaluation study using PanLeucoGating
as a single-platform protocol. Cytometry B Clin Cytom 2003, 55(1):8–13.
40. Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, Mudzori J:
Evaluation of the Partec flow cytometer against the BD FACSCalibur
system for monitoring immune responses of human immunodeficiency
virus-infected patients in Zimbabwe. Clin Vaccine Immunol 2007,
14(3):293–298.
41. Mbopi-Keou FX, Ongolo-Zogo P, Angwafo F 3rd, Ndumbe PM, Belec L:
High impact of mobile units for mass HIV testing in Africa. AIDS 2007,
21(14):1994–1996.
42. Barbesti S, Soldini L, Carcelain G, Guignet A, Colizzi V, Mantelli B, Corvaglia
A, Tran-Minh T, Dorigatti F, Autran B, et al: A simplified flow cytometry
method of CD4 and CD8 cell counting based on thermoresistant
reagents: implications for large scale monitoring of HIV-infected patients
in resource-limited settings. Cytometry B Clin Cytom 2005, 68(1):43–51.
43. Larsen CH: The fragile environments of inexpensive CD4+ T-cell
enumeration in the least developed countries: strategies for accessible
support. Cytometry B Clin Cytom 2008, 74(Suppl 1):S107–S116.
44. Cassens U, Gohde W, Kuling G, Groning A, Schlenke P, Lehman LG, Traore Y,
Servais J, Henin Y, Reichelt D, et al: Simplified volumetric flow cytometry
allows feasible and accurate determination of CD4 T lymphocytes in
immunodeficient patients worldwide. Antivir Ther 2004, 9(3):395–405.
45. Reimann KA, O’Gorman MR, Spritzler J, Wilkening CL, Sabath DE, Helm K,
Campbell DE: Multisite comparison of CD4 and CD8 T-lymphocyte
counting by single- versus multiple-platform methodologies: evaluation
of Beckman Coulter flow-count fluorospheres and the tetraONE system.
The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab
Immunol 2000, 7(3):344–351.
46. World Health Organization: Towards Universal Access Scaling up priority HIV/
AIDS interventions in the health sector. 2010. Available at: http://www.who.
int/hiv/pub/2010progressreport/summary_en.pdf.
doi:10.1186/1756-0500-6-169
Cite this article as: Koyalta et al.: Single-platform, volumetric, CD45-
assisted pan-leucogating flow cytometry for CD4 T lymphocytes
monitoring of HIV infection according to the WHO recommendations
for resource-constrained settings. BMC Research Notes 2013 6:169. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
